Novo Nordisk A/SLong
Buy Opportunity for NVO
Novo Nordisk A/S – Financial Summary and Outlook (2024):
Sales Growth: Up 23% in Danish kroner (DKK 204.7 billion) and 24% at constant exchange rates (CER).
Operating Profit: Increased by 21% (DKK 91.6 billion).
Net Profit: Rose 18% to DKK 72.8 billion.
Product Highlights:
Wegovy (Obesity): Sales surged 48% in Q3 (DKK 17.3 billion).
Ozempic (Diabetes): Slight sales dip but remains a key contributor.
Challenges:
CagriSema Trial: Missed expected weight-loss targets, leading to stock decline.
Outlook:
Adjusted sales growth forecast: 23%-27%; operating profit: 21%-27% (CER).
Focus remains on high-demand products (Wegovy, Ozempic) and R&D for future growth.
Sales Growth: Up 23% in Danish kroner (DKK 204.7 billion) and 24% at constant exchange rates (CER).
Operating Profit: Increased by 21% (DKK 91.6 billion).
Net Profit: Rose 18% to DKK 72.8 billion.
Product Highlights:
Wegovy (Obesity): Sales surged 48% in Q3 (DKK 17.3 billion).
Ozempic (Diabetes): Slight sales dip but remains a key contributor.
Challenges:
CagriSema Trial: Missed expected weight-loss targets, leading to stock decline.
Outlook:
Adjusted sales growth forecast: 23%-27%; operating profit: 21%-27% (CER).
Focus remains on high-demand products (Wegovy, Ozempic) and R&D for future growth.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.